The Ph2 failure of Galecto's GB0139 is a salient reminder that IPF remains a grave yard for clinical trials while patients continue to settle for the only two approved drugs with horrible tolerability profiles. More biological understanding of the disease process is needed before we can have an efficacious drug that can stabilize or even reverse the disease.
Comments